Structure via PubChem · Public domain (PubChem)
chlorotrianisene
Sign in to saveAlso known as chlortrianisestrol, Tace®, Chlortrianizen, Chlortrianisoestrolum, Chlortrianisen, Chlorotrianizen, Chlorotrianisine, Chlorestrolo
Chlorotrianisene (CTA), also known as 'tri-p-anisylchloroethylene (TACE) and sold under the brand name Tace' among others, is a nonsteroidal estrogen related to diethylstilbestrol (DES) which was previously used in the treatment of menopausal symptoms and estrogen deficiency in women and prostate cancer in men, among other indications, but has since been discontinued and is now no longer available. It is taken by mouth.
Chemical data
- Formula
- C23H21ClO3
- Molecular weight
- 380.9 g/mol
- IUPAC name
- 1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1982
- Admin. routes
- oral
- Indications
- hepatocellular carcinoma, liver cancer
via ChEMBL · EBI
Research
131 papers- Chlorotrianisene.IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans · 1979
- The menopause.British medical journal · 1971
- Monooxygenase-mediated activation of chlorotrianisene (TACE) in covalent binding to rat hepatic microsomal proteins.Drug metabolism and disposition: the biological fate of chemicals · 1987
- Role of P-450c in the formation of a reactive intermediate of chlorotrianisene (TACE) by hepatic microsomes from methylcholanthrene-treated rats.Drug metabolism and disposition: the biological fate of chemicals · 1990
- Treatments for suppression of lactation.The Cochrane database of systematic reviews · 2012
via PubMed
~7 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Chemistry
- History
- Society and culture
- Generic names
- Brand names
- Availability
- References
Chlorotrianisene (CTA), also known as 'tri-p-anisylchloroethylene (TACE) and sold under the brand name Tace' among others, is a nonsteroidal estrogen related to diethylstilbestrol (DES) which was previously used in the treatment of menopausal symptoms and estrogen deficiency in women and prostate cancer in men, among other indications, but has since been discontinued and is now no longer available. It is taken by mouth.
CTA is an estrogen, or an agonist of the estrogen receptors, the biological target of estrogens like estradiol. It is a high-efficacy partial estrogen and shows some properties of a selective estrogen receptor modulator, with predominantly estrogenic activity but also some antiestrogenic activity. CTA itself is inactive and is a prodrug in the body.
Excerpted from Wikipedia’s “chlorotrianisene” article, available under the CC BY-SA 4.0 licence.